A5009932385- Cell Adhesion Molecules Research
- Cellular Mechanics and Interactions
- Cancer Cells and Metastasis
- Liver physiology and pathology
- Protease and Inhibitor Mechanisms
- Advanced Breast Cancer Therapies
- Liver Diseases and Immunity
- Signaling Pathways in Disease
- Liver Disease Diagnosis and Treatment
- TGF-β signaling in diseases
- Angiogenesis and VEGF in Cancer
- 14-3-3 protein interactions
- Cancer, Stress, Anesthesia, and Immune Response
- Wnt/β-catenin signaling in development and cancer
- HER2/EGFR in Cancer Research
- S100 Proteins and Annexins
- Cellular transport and secretion
- Hormonal Regulation and Hypertension
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hippo pathway signaling and YAP/TAZ
- Cell Image Analysis Techniques
- PI3K/AKT/mTOR signaling in cancer
University of Pennsylvania
2021-2024
Institut de Recherche en Santé, Environnement et Travail
2018-2023
École des Hautes Études en Santé Publique
2018-2020
Inserm
2018-2020
Université de Rennes
2018
Centre National de la Recherche Scientifique
2016
Université de Reims Champagne-Ardenne
2016
Abstract Cells interpret cues from and interact with fibrous microenvironments through the body based on mechanics organization of these environments phenotypic state cell. This in turn regulates mechanoactive pathways, such as localization mechanosensitive factors. Here, we leverage microscale heterogeneity inherent to engineered fiber produce a large morphologic data set, across multiple cells types, while simultaneously measuring mechanobiological response (YAP/TAZ nuclear localization)...
Activation of hepatic stellate cells (HSC) is a critical process involved in liver fibrosis. Several miRNAs are implicated gene regulation during this but their exact and respective contribution still incompletely understood. Here we propose an integrative approach miRNA-regulatory networks to predict new targets.miRNA regulatory activated HSCs were built using lists validated the CyTargetLinker tool. The resulting graphs filtered according public transcriptomic data reduced analysed through...
The epithelial mesenchymal transition (EMT) is a key process for cancer cell invasion and migration. This complex program whereby tumor cells loose polarity acquire phenotype driven by the regulation of cell-cell adhesion cell-substrate interactions. We recently described association ADAM12 with EMT we now use immunoprecipitation proteomic approaches to identify interacting partners during EMT. twenty proteins that are involved in molecular mechanisms associated adhesion/invasion processes....
<title>Abstract</title> Collagen plays a critical role in regulating breast cancer progression and therapeutic resistance. An improved understanding of both the features drivers tumor-permissive -restrictive collagen matrices are to improve prognostication develop more effective strategies. In this study, using combination vitro, vivo silico experiments, we show that type III (Col3) tumor-restrictive human cancer. We demonstrate Col3-deficient, fibroblasts produce drive cell proliferation...
Low-Density Lipoprotein Receptor-related Protein-1 (LRP-1) is a multifunctional matricellular receptor composed of large ligand-binding subunit (515-kDa α-chain) associated with short trans-membrane (85-kDa β-chain). LRP-1, which exhibits both endocytosis and cell signaling properties, plays key role in tumor invasion by regulating the activity proteinases such as matrix metalloproteinases (MMPs). LRP-1 shed at surface membrane-type 1 MMP (MT1-MMP) disintegrin metalloproteinase-12 (ADAM-12)....
Adamalysins, a family of metalloproteinases containing disintegrin and (ADAMs) ADAM with thrombospondin motifs (ADAMTSs), belong to the matrisome play important roles in various biological pathological processes, such as development, immunity cancer. Using liver cancer dataset from International Cancer Genome Consortium, we developed an extensive silico screening that identified cluster adamalysins co-expressed livers patients hepatocellular carcinoma (HCC). Within this cluster, ADAMTS12...
Abstract ER+/HER2- advanced or metastatic breast cancers represents a large patient population served by CDK4/6 inhibitors combined with hormonal therapy as standard of care. As acquired resistance emerges, molecular profiling indicates about &gt; 100 different mutations render resistance, creating challenges for treating physicians, patients, and the healthcare system broadly. The aim our work is to maintain consolidation this developing targeted therapies key fundamental mechanism at...